Azithromycin Dosing for Community-Acquired Pneumonia
For adults with community-acquired pneumonia, give azithromycin 500 mg once daily on Day 1, followed by 250 mg once daily on Days 2-5 (total 5-day course). For children ≥6 months with CAP, give 10 mg/kg on Day 1, then 5 mg/kg once daily on Days 2-5.
Adult Dosing
The standard regimen is straightforward 1, 2:
- Day 1: 500 mg as a single dose
- Days 2-5: 250 mg once daily
- Total duration: 5 days
- Can be taken with or without food
Alternative Adult Regimen
A 3-day course (500 mg once daily for 3 days) is FDA-approved for acute bacterial exacerbations of COPD but not specifically for CAP 2. However, research demonstrates that azithromycin 1 gram once daily for 3 days achieves 92.6% clinical success in mild-to-moderate CAP, non-inferior to 7-day amoxicillin-clavulanate 3. Despite this evidence, the 2019 ATS/IDSA guidelines recommend the standard 5-day regimen for outpatient CAP 1.
Pediatric Dosing (≥6 months old)
The preferred regimen for children with CAP is weight-based 4, 2:
Standard 5-Day Course (Preferred)
- Day 1: 10 mg/kg as a single dose
- Days 2-5: 5 mg/kg once daily
- Maximum: Do not exceed adult doses
Practical Weight-Based Dosing Table
Using 200 mg/5 mL suspension 2:
- 5 kg (11 lbs): 1.25 mL Day 1, then 0.625 mL Days 2-5
- 10 kg (22 lbs): 2.5 mL Day 1, then 1.25 mL Days 2-5
- 20 kg (44 lbs): 5 mL Day 1, then 2.5 mL Days 2-5
- 30 kg (66 lbs): 7.5 mL Day 1, then 3.75 mL Days 2-5
- 40 kg (88 lbs): 10 mL Day 1, then 5 mL Days 2-5
Alternative 3-Day Pediatric Regimen
10 mg/kg once daily for 3 days is FDA-approved for acute bacterial sinusitis and otitis media, but effectiveness for CAP has not been established in children 2.
Clinical Context and Rationale
When to Use Azithromycin in CAP
For outpatient adults without comorbidities: Azithromycin monotherapy is appropriate only if local pneumococcal macrolide resistance is <25% 1. Otherwise, combine with amoxicillin or use doxycycline instead.
For outpatient adults with comorbidities: Use azithromycin in combination with amoxicillin/clavulanate or a cephalosporin, not as monotherapy 1.
For hospitalized adults: Azithromycin should be combined with a beta-lactam (ampicillin, ceftriaxone, or cefotaxime). Recent evidence shows azithromycin plus beta-lactam reduces mortality compared to doxycycline plus beta-lactam (OR 0.71,95% CI 0.56-0.9) 5.
For children ≥5 years: Azithromycin is preferred for atypical pathogens (Mycoplasma pneumoniae, Chlamydophila pneumoniae). For children <5 years with presumed bacterial CAP, amoxicillin is first-line; add azithromycin if atypical pneumonia cannot be excluded 4.
Duration Considerations
While 3-day courses show efficacy in research settings 3, 6, 7, the 5-day regimen remains the guideline-recommended standard 1, 2. Recent evidence supports shortening treatment to 3 days for patients achieving clinical stability by Day 3, but this applies to all antibiotics, not specifically azithromycin 8.
Treatment courses of 10 days have been most extensively studied in children, though shorter courses may be equally effective for mild disease 4.
Important Caveats
Macrolide resistance: Despite 60.8% macrolide resistance in pneumococcal ICU CAP, azithromycin still reduces mortality when combined with beta-lactams (adjusted OR 0.27, p=0.024), suggesting immunomodulatory benefits beyond antimicrobial activity 9.
Renal impairment: No dose adjustment needed for GFR 10-80 mL/min. Use caution with GFR <10 mL/min (35% increase in AUC) 2.
Hepatic impairment: Pharmacokinetics not established; no specific dose adjustments available 2.
Adverse effects: Gastrointestinal symptoms (diarrhea 4-7%, nausea 3-5%, abdominal pain 2-5%) are most common. Azithromycin is better tolerated than amoxicillin/clavulanate in children (11.3% vs 31% treatment-related adverse events, p<0.05) 10.